Special Report: multiple molecular testing of cancers to identify targeted therapies
BlueCross BlueShield Association
Record ID 32013000680
English
Authors' objectives:
The objective of this Special Report is to review important concepts underlying the use of multiple molecular testing to guide cancer treatment. Issues and problems underlying the assessment of efficacy of such strategies will be discussed. Published studies that use multiple molecular testing methods to select targeted therapies and that report patient outcomes will be presented.
Authors' recommendations:
Use of multiple molecular testing to assist in making treatment decisions for cancer patients is rapidly evolving. Strong evidence of clinical effectiveness of this approach is not available, and a number of issues remain to be solved, particularly patient selection. Different approaches may be taken to the interpretation of multiple molecular marker panels. Clinical trials to determine the effectiveness of this approach will be challenging to complete.
Details
Project Status:
Completed
Year Published:
2013
URL for published report:
http://www.bcbs.com/blueresources/tec/vols/28/28_01.pdf
URL for additional information:
http://www.bcbs.com/blueresources/tec/vols/28/multiple-molecular-testing.html
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Blue Cross Blue Shield Insurance Plans
- DNA Mutational Analysis
- Technology Assessment, Biomedical
- United States
- United States Food and Drug Administration
- Biomarkers, Tumor
- Molecular Targeted Therapy
- Mutation
- Neoplasms
Contact
Organisation Name:
BlueCross BlueShield Association
Contact Address:
BlueCross BlueShield Association, Technology Evaluation Center, 225 North Michigan Ave, Chicago, Illinois, USA. Tel: 888 832 4321
Contact Name:
tec@bcbsa.com
Contact Email:
tec@bcbsa.com
Copyright:
BlueCross BlueShield Association (BCBS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.